UPMC-backed cancer immunotherapy developer BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target for its close.

Pitt spinout BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target size.

Wind, Shanghai Zhangjiang Hi-tech Park Development and Chengxin Credit Ratings all backed the mapping technology provider's series A-plus round.

The Oxford-linked oncology drug developer has raised the money from new and existing backers, and will use the cash to boost its product pipeline.

The Eli Lilly and Wuxi AppTec-backed oncology drug developer has raised the money from new and existing backers, and will use the cash to boost its product pipeline.

The Alibaba-backed rail network software developer pushed its overall funding near the $130m mark in a round led by Sanno Capital.

The GV-backed market intelligence platform developer has pushed its total funding past $150m in a series E round led by WestCap Group.

Tencent led an $83.9m round for the insurance technology developer, which counts Axel Springer and ProSiebenSat.1 among its earlier investors.

The Minth Group, Zoll Medical and Abiomed-backed medical device developer has raised at least $217m in total after closing additional series D funding.

Intel Capital chipped in as part of a series B round set to drive product development and growth for food supply insights provider Gro Intelligence.